Mild Cognitive Impairment Staging Yields Genetic Susceptibility, Biomarker, and Neuroimaging Differences
Open Access
- 5 June 2020
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 12, 139
- https://doi.org/10.3389/fnagi.2020.00139
Abstract
Introduction: While Alzheimer’s disease (AD) is divided into severity stages, mild cognitive impairment (MCI) remains a solitary construct despite clinical and prognostic heterogeneity. This study aimed to characterize differences in genetic, cerebrospinal fluid (CSF), neuroimaging, and neuropsychological markers across clinician-derived MCI stages. Methods: Vanderbilt Memory & Aging Project participants with MCI were categorized into 3 severity subtypes at screening based on neuropsychological assessment, functional assessment, and Clinical Dementia Rating interview, including mild (n = 18, 75 ± 8 years), moderate (n = 89 72 ± 7 years), and severe subtypes (n = 18, 78 ± 8 years). At enrollment, participants underwent neuropsychological testing, 3T brain magnetic resonance imaging (MRI), and optional fasting lumbar puncture to obtain CSF. Neuropsychological testing and MRI were repeated at 18-months, 3-years, and 5-years with a mean follow-up time of 3.3 years. Ordinary least square regressions examined cross-sectional associations between MCI severity and apolipoprotein E (APOE)-ε4 status, CSF biomarkers of amyloid beta (Aβ), phosphorylated tau, total tau, and synaptic dysfunction (neurogranin), baseline neuroimaging biomarkers, and baseline neuropsychological performance. Longitudinal associations between baseline MCI severity and neuroimaging and neuropsychological trajectory were assessed using linear mixed effects models with random intercepts and slopes and a follow-up time interaction. Analyses adjusted for baseline age, sex, race/ethnicity, education, and intracranial volume for MRI models. Results: Stages differed at baseline on APOE-ε4 status (early < middle = late; p-values < 0.03) and CSF Aβ (early > middle = late), phosphorylated and total tau (early = middle < late; p-values < 0.05), and neurogranin concentrations (early = middle < late; p-values < 0.05). MCI stage related to greater longitudinal cognitive decline, hippocampal atrophy, and inferior lateral ventricle dilation (early < late; p-values < 0.03). Discussion: Clinician staging of MCI severity yielded longitudinal cognitive trajectory and structural neuroimaging differences in regions susceptible to AD neuropathology and neurodegeneration. As expected, participants with more severe MCI symptoms at study entry had greater cognitive decline and gray matter atrophy over time. Differences are likely attributable to baseline differences in amyloidosis, tau, and synaptic dysfunction. MCI staging may provide insight into underlying pathology, prognosis, and therapeutic targets.Funding Information
- Alzheimer’s Association
- National Institutes of Health (R01-AG034962, R01-AG056534, R01-NS100980, K24-AG046373, K23-AG030962, K23-AG045966, K23-AG048347, K01-AG049164, K12-HD043483, F30-AG064847, T32-GM007347, UL1-TR000445, S10-OD023680)
- Vanderbilt Memory and Alzheimer’s Center
- Torsten Söderbergs Stiftelse
- Knut och Alice Wallenbergs Stiftelse
- European Research Council
This publication has 52 references indexed in Scilit:
- Tau phosphorylation affects its axonal transport and degradationNeurobiology of Aging, 2013
- The Synaptic Accumulation of Hyperphosphorylated Tau Oligomers in Alzheimer Disease Is Associated With Dysfunction of the Ubiquitin-Proteasome SystemThe American Journal of Pathology, 2012
- Dissociation between Brain Amyloid Deposition and Metabolism in Early Mild Cognitive ImpairmentPLOS ONE, 2012
- An automated tool for detection of FLAIR-hyperintense white-matter lesions in Multiple SclerosisNeuroImage, 2012
- Human apoE Isoforms Differentially Regulate Brain Amyloid-β Peptide ClearanceScience Translational Medicine, 2011
- Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer diseaseAnnals of Neurology, 2010
- Alzheimer's patients engage an alternative network during a memory taskAnnals of Neurology, 2005
- The Clinical Dementia Rating (CDR)Neurology, 1993
- Neuropathological stageing of Alzheimer-related changesActa Neuropathologica, 1991
- “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinicianJournal of Psychiatric Research, 1975